

Victoria Securities Company, Victoria, Texas, and thereby engage in securities brokerage activities, pursuant to § 225.25(b)(15) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, February 16, 1996.

Jennifer J. Johnson,
Deputy Secretary of the Board.

[FR Doc. 96-4052 Filed 2-22-96; 8:45 am]

BILLING CODE 6210-01-F

COMMISSION OF FINE ARTS

Notice of Meeting

The Commission of Fine Arts' next meeting is scheduled for 14 March 1996 at 10:00 a.m. the Commission's offices in the Pension Building, Suite 312, Judiciary Square, 441 F Street, N.W., Washington, D.C. 20001 to discuss various projects affecting the appearance of Washington, D.C., including buildings, memorials, parks, etc.; also matters of design referred by other agencies of the government.

Inquiries regarding the agenda and requests to submit written or oral statements should be addressed to Charles H. Atherton, Secretary, Commission of Fine Arts, at the above address or call the above number.

Dated in Washington, D.C. 15 February 1996.

Charles H. Atherton,
Secretary.

[FR Doc. 96-4110 Filed 2-22-96; 8:45 am]

BILLING CODE 6330-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Dietary Supplement Labels Commission; Meeting

AGENCY: Office of Disease Prevention and Health Promotion, HHS.

ACTION: Commission on Dietary Supplement Labels: Announcement of Appointment; Notice of Meeting #2; Opportunity to Provide Comments.

SUMMARY: The Department of Health and Human Services (HHS) is (a) providing notice of the second meeting of the Commission on Dietary Supplement Labels, and (b) soliciting oral and written comments.

DATES: (1) The Commission will meet March 8, 1996, from 8:30 a.m. to 4:30 p.m. Central Time at the Radisson Hotel Salt Lake City Airport (Utah). (2) Written comments on the scope and intent of the Commission's objectives may be submitted up to 5:00 p.m. e.s.t. on June 30, 1996.

FOR FURTHER INFORMATION CONTACT: Kenneth D. Fisher, Ph.D., Executive Director, Commission on Dietary Supplement Labels, Office of Disease Prevention and Health Promotion, Room 738G, Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, D.C. 20201, (202) 205-5968.

SUPPLEMENTARY INFORMATION:

Commission's Task

Public Law 103-417, Section 12, authorized the establishment of a Commission on Dietary Supplement Labels whose seven members have been appointed by the President. The appointments to the Commission by the President and the establishment of the Commission by the Secretary of Health and Human Services reflect the commitment of the President and the Secretary to the development of a sound and consistent regulatory policy on labeling of dietary supplements.

The Commission is charged with conducting a study and providing recommendations for regulation of label claims and statements for dietary supplements, including the use of supplemental literature in connection with their sale and, in addition, procedures for evaluation of label claims. The Commission is expected to evaluate how best to provide truthful, scientifically valid, and nonmisleading information to consumers in order that they may make informed health care choices for themselves and their families. The Commission's study report may include recommendations on legislation, if appropriate and necessary.

Announcement of Meeting

The Commission's second meeting will be March 8, 1996, 8:30 a.m. to 4:30 p.m. Central Time. The meeting will be held at the Radisson Hotel Salt Lake City Airport Coventary Room, (Utah). The agenda will include (a) oral comments from interested parties and the general public, (b) identification of additional information needs, and (c) discussion of dietary supplement label information.

Public Participation at Meeting

The meeting is open to the public. However, space is limited. Both oral and written comments from the public will be accepted, but oral comments at the meeting will be limited to a maximum of five minutes per presenter; thus, organizations and persons that wish to make their views known to the Commission should use the time for oral presentation to summarize their written comments. Members of the Commission may wish to question the presenters

following each oral presentation. Please request the opportunity to present oral comments in writing and provide nine (9) copies of the written comments from which the oral presentation is abstracted to the address above by March 4, 1996. If you will require a sign language interpreter, please call Sandra Saunders (202) 260-0375 by 4:30 e.s.t. on March 4, 1996.

Written Comments

By this notice, the Commission is soliciting submission of written comments, views, information and data pertinent to Commission's task. Comments should be sent to Kenneth D. Fisher, Executive Director of the Commission at the Office of Disease Prevention and Health Promotion, Room 738G, Hubert Humphrey Building, 200 Independence Avenue SW., Washington D.C. 20201, 5:00 p.m. e.s.t. on June 30, 1996.

Dated: February 15, 1996.

Claude Earl Fox,

Deputy Assistant Secretary for Health (Disease Prevention and Health Promotion), U.S. Department of Health and Human Services.

[FR Doc. 96-4101 Filed 2-22-96; 8:45 am]

BILLING CODE 4160-17-M

Food and Drug Administration

[Docket No. 96F-0051]

Ciba-Geigy Corp.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Ciba-Geigy Corp. has filed a petition proposing that the food additive regulations be amended to expand the safe use of oxidized bis(hydrogenated tallow alkyl)amines as a process stabilizer for polypropylene homo- and copolymers and high-density polyethylene homo- and copolymers intended for use in contact with food.

DATES: Written comments on the petitioner's environmental assessment by March 25, 1996.

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA305), Food and Drug Administration, 12420 Parklawn Dr., Rm. 1-23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Mark A. Hepp, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW.,